ScreenerHero

FULCFulcrum Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · fulcrumtx.com
3.830USD-2.05%Mkt Cap: 292.22M $P/E: —

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United St…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap292.22M $
Enterprise Value-19.82M $
Revenue (TTM)—
Gross Profit-56.64M $
Net Income (TTM)-74.88M $
Revenue/Share—
Last Price3.830 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees9
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.89
PEG—
EV/EBITDA0.23
EV/Revenue—
P/S—
P/B0.95
EPS (TTM)-1.19
EPS (Forward)-0.49
52W Range
2.9107% of range15.74
52W High15.74 USD
52W Low2.910 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-21.46%
ROA-20.44%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-60.06M $
CapEx (TTM)314.00K $
FCF Margin—
FCF Yield-12.79%
Net Debt-313.56M $
Net Debt/EBITDA3.67
Balance Sheet
Debt/Equity0.02
Current Ratio31.35
Quick Ratio31.16
Book Value/Sh4.073 USD
Cash/Share4.179 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating3.2 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.500 USD
Upside (mean)-8.6%
Target Range3.000 USD – 4.000 USD
$3.000-8.6% to mean$4.000
# Analysts4
Ownership
Shares Out.76.30M
Float63.49M
Insiders3.35%
Institutions105.63%
Short Interest
Short Ratio4.0d
Short % Float8.78%
Short % Out.8.69%
Shares Short6.63M
Short (prev mo.)6.43M
Technical
SMA 503.687 (+3.9%)
SMA 2007.574 (-49.4%)
Beta2.58
S&P 52W Chg18.16%
Avg Vol (30d)1.68M
Avg Vol (10d)2.12M
Technical Indicators
RSI (14)51.7
MACD-0.0071
MACD Signal-0.0402
MACD Hist.+0.0331
BB Upper3.908 USD
BB Middle3.749 USD
BB Lower3.590 USD
BB Width8.47%
ATR (14)0.1603 USD
Vol Ratio (20d)0.88x